UY27675A1 - Combinaciones de un ligado alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2 - Google Patents

Combinaciones de un ligado alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2

Info

Publication number
UY27675A1
UY27675A1 UY27675A UY27675A UY27675A1 UY 27675 A1 UY27675 A1 UY 27675A1 UY 27675 A UY27675 A UY 27675A UY 27675 A UY27675 A UY 27675A UY 27675 A1 UY27675 A1 UY 27675A1
Authority
UY
Uruguay
Prior art keywords
inhibitor
combinations
selective
cyclooxygenasa
alfa
Prior art date
Application number
UY27675A
Other languages
English (en)
Inventor
Charles P Taylor Jr
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UY27675A1 publication Critical patent/UY27675A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La invención se refiere a una combinación que comprende un inhibidor selectivo de la COX-2 o una de sus sales farmacéuticamente aceptable y un ligado alfa-2-delta, o una de sus sales farmacéuticamente aceptables, y valdecoxib, y celecoxib. Los ejemplos de los ligados alfa-2-delta incluyen gabapentina, opregaballina, ácido (3S,4S)-(1-aminometil-3,4-dimetil-ciclopentil)-acético, e hidrocloruro de 3.(1- aminometil- ciclohexilmetil)-4H-(1,2,4) oxadiazol-5-ona. Las combinaciones son útiles para tratar ciertas enfermedades que incluyen el dano del cartílago, inflamación, el dolor, y la artritis.
UY27675A 2002-02-22 2003-02-19 Combinaciones de un ligado alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2 UY27675A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35929502P 2002-02-22 2002-02-22
US40436502P 2002-08-19 2002-08-19

Publications (1)

Publication Number Publication Date
UY27675A1 true UY27675A1 (es) 2003-09-30

Family

ID=27760521

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27675A UY27675A1 (es) 2002-02-22 2003-02-19 Combinaciones de un ligado alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2

Country Status (21)

Country Link
US (1) US20030199567A1 (es)
EP (1) EP1480639A1 (es)
JP (1) JP2005523281A (es)
KR (1) KR20040085216A (es)
CN (1) CN1635887A (es)
AR (1) AR038531A1 (es)
AU (1) AU2003246864A1 (es)
BR (1) BR0307906A (es)
CA (1) CA2476438A1 (es)
CO (1) CO5611109A2 (es)
HN (1) HN2003000071A (es)
IL (1) IL162932A0 (es)
MX (1) MXPA04008175A (es)
NO (1) NO20043947L (es)
PA (1) PA8567201A1 (es)
PE (1) PE20031052A1 (es)
PL (1) PL372210A1 (es)
RU (1) RU2286151C2 (es)
TW (1) TW200303214A (es)
UY (1) UY27675A1 (es)
WO (1) WO2003070237A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2509605C (en) * 2002-12-13 2010-10-05 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
CN1791399A (zh) * 2003-03-21 2006-06-21 戴诺根医药品公司 用α2δ亚基钙通道调节剂和平滑肌调节剂一起治疗下泌尿道病症的方法
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
MXPA06002789A (es) * 2003-09-12 2006-06-14 Pfizer Combinaciones que comprenden ligandos alfa-2-delta.
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
WO2005041976A2 (en) * 2003-10-23 2005-05-12 Medtronic, Inc. Injectable gabapentin compositions
US7888351B2 (en) * 2006-04-11 2011-02-15 Novartis Ag Organic compounds
JP2010513357A (ja) * 2006-12-22 2010-04-30 ノバルティス アーゲー Dpp−iv阻害剤としての1−アミノメチル−1−フェニル−シクロヘキサン誘導体
CA2723358A1 (en) * 2008-05-05 2009-11-12 Allison B. Reiss Method for improving cardiovascular risk profile of cox inhibitors
KR101851120B1 (ko) * 2008-09-05 2018-04-23 그뤼넨탈 게엠베하 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀과 항간질제의 약제학적 병용물
KR102631399B1 (ko) 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
JP2023548380A (ja) * 2020-10-28 2023-11-16 トレモー・ファーマシューティカルズ・インコーポレイテッド 非水溶性cox-2阻害の水性製剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5420270A (en) * 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5352638A (en) * 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
DE69832712T2 (de) * 1997-09-08 2006-06-22 Warner-Lambert Company Llc Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
JP2002508352A (ja) * 1997-12-16 2002-03-19 ワーナー−ランバート・カンパニー 4(3)置換−4(3)−アミノメチル−(チオ)ピラン又はピペリジン誘導体(=ガバペンチン類似体)、それらの製法および神経病理学的疾患の治療における使用
AU3216600A (en) * 1999-03-10 2000-09-28 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
BR0008059A (pt) * 1999-12-08 2002-03-26 Pharmacia Corp Composições de valdecoxib

Also Published As

Publication number Publication date
AR038531A1 (es) 2005-01-19
PL372210A1 (en) 2005-07-11
HN2003000071A (es) 2003-11-24
CA2476438A1 (en) 2003-08-28
JP2005523281A (ja) 2005-08-04
PA8567201A1 (es) 2003-11-12
CO5611109A2 (es) 2006-02-28
US20030199567A1 (en) 2003-10-23
AU2003246864A1 (en) 2003-09-09
RU2286151C2 (ru) 2006-10-27
EP1480639A1 (en) 2004-12-01
WO2003070237A1 (en) 2003-08-28
KR20040085216A (ko) 2004-10-07
RU2004125609A (ru) 2006-01-27
CN1635887A (zh) 2005-07-06
TW200303214A (en) 2003-09-01
PE20031052A1 (es) 2003-12-24
NO20043947L (no) 2004-09-21
IL162932A0 (en) 2005-11-20
MXPA04008175A (es) 2004-11-26
BR0307906A (pt) 2004-12-21

Similar Documents

Publication Publication Date Title
UY27675A1 (es) Combinaciones de un ligado alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2
CO5600999A2 (es) Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra
DK1297851T3 (da) Inhibering af histondeacetylasesom behandling af hjertehypertrofi
AR022022A1 (es) Combinaciones de inhibidores del transporte de acido ileo-biliar con agentes secuestrantes de acido biliar, para prescripciones cardiovasculares
PA8592101A1 (es) Nuevos enantiomeros (r) y (s) de derivados del acido tiofeno hidroxamico
AR046970A1 (es) Esteres de fosfato de florfenicol
RS52625B (en) FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR TREATMENT AND PREVENTION OF DISEASES AND DISEASES
BR0306675A (pt) Dispositivo para prover um número de produtos
EA200100958A1 (ru) Производные 4,5-диарил-3(2h)-фуранона как ингибиторы циклооксигеназы-2
ECSP088984A (es) Derivados de triazol ii
ECSP099364A (es) Composiciones y metodos antiparasitarios utilizando indoles relacionados a diindolilmetano
CO2021005070A2 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
CY1105429T1 (el) Φαρμακευτικη συνθεση συνδυαζουσα τενατοπραζολη και ενα αντιφλεγμονωδες
PE20020598A1 (es) Combinacion de agonistas de gaba e inhibidores de aldosa-reductasa
UY28076A1 (es) Procedimiento para aumentar el rendimiento de las leguminosas.
CO2022015630A2 (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CY1121477T1 (el) Χρηση αλφα-κετογλουταρικου οξεος και 5-υδροξυ-μεθυλοφουρφουραλης για τη μειωση του οξειδωτικου στρες
CR20220199A (es) Inhibidores del factor d del complemento para administración oral
HN2003000040A (es) Acidos 3-(imidazolil)-2-aminopropanoicos
GT200000221A (es) Inhibidores de la proteinasa c del procolageno.
BR0011801A (pt) Inibidores de benzamida substituìda para 3c protease de rinovìrus
CL2023003168A1 (es) Moduladores de trex1
DOP2003000577A (es) Combinaciones de un ligando alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2
ES2091031T3 (es) Uso de acido hialuronico para prevenir la reestenosis arterial.
UA45242S (uk) 1.-2. комплект етикеток

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150520